Augmentation of the in vitro humoral immune response by pharmacologic agents. II: comparison of the effects of antiproliferative agents with DBcAMP.
We have compared the stimulatory activity of DBcAMP with various antiproliferative agents on the induction of the humoral immune response. When they are present only during an early stage of immune induction, DBcAMP, colcemid, cytosine-arabinoside, hydroxy urea, and high specific activity 3H-thymidine can all enhance the primary 19s antibody response to SRBC. In contrast, each of these agents inhibits the PFC response, when they are incubated with the cells during late stages of induction of humoral immunity. Because all of these agents can inhibit proliferation of cultured cells, the results suggested that DBcAMP and other agents that elevate cAMP could augment humoral immunity via their effects on cellular proliferation. However, we also found that although each agent could modulate induction of the immune response to SRBC, only DBcAMP produced a dose- and time-dependent augmentation of the response to DLF. We conclude that although antiproliferative effects of drugs may contribute to augmentation of some humoral antibody responses, this effect alone is insufficient to account for the mechanism by which agents that elevate intracellular levels of cAMP produce enhancement of humoral immunity.
D000818:Animals; D000917:Antibody Formation / Q000187:drug effects*; D003994:Bucladesine / Q000494:pharmacology*; D002478:Cells, Cultured; D000242:Cyclic AMP / Q000378:metabolism; D003561:Cytarabine / Q000494:pharmacology*; D003703:Demecolcine / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006918:Hydroxyurea / Q000494:pharmacology*; D051379:Mice; D013154:Spleen / Q000276:immunology
D003561:Cytarabine; D003994:Bucladesine; D000242:Cyclic AMP; D006918:Hydroxyurea; D003703:Demecolcine